Latest Indivior News & Updates

See the latest news and media coverage for Indivior. We track all announcements, press releases, and industry mentions in real time, all in one place.

Indivior

Specialty pharmaceutical company focused on opioid use disorder

indivior.com

Headquarters: Richmond, United States
Company type: Public company
Number of employees: 1,000–5,000
Industry: Pharmaceuticals

Last updated Today

Latest news about Indivior

In short: Indivior agreed to merge with Supernus in a $2.2 billion deal and reported strong Q2 2026 earnings with raised financial guidance.

Company announcements

August 6 Indivior

Indivior completed its delisting from the London Stock Exchange

The secondary listing ended July 25, 2025; Nasdaq remains its primary listing.

August 3 Indivior

Indivior and Supernus to combine in $2.2B merger

The tax-free all-stock merger of equals expects $125M annual cost synergies and will create Supernus, Inc. with Jack Khattar as CEO.

August 3 Indivior

Indivior reports Q2 2026 financial results and raises guidance

Total net revenue rose 14% to $343 million, with record SUBLOCADE revenue and adjusted EBITDA, and the company announced a merger with Supernus.

April 30 Indivior

Indivior reports Q1 2026 financial results and raises guidance

Net revenue rose 19% to $317M, SUBLOCADE grew 32%, and adjusted EBITDA increased 112%.

Media coverage

Yesterday Ad hoc news

The Indivior stock is trading steadily after the latest quarterly figures

The Indivior stock shows stability after the latest quarterly figures, while investors are reassessing the valuation and outlook of the specialty pharma company.

August 29 Business Wire

INDV Stock Alert: Halper Sadeh LLC is Investigating Whether Indivior Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders

NEW YORK--(BUSINESS WIRE)--Aug 29, 2026...

August 21 Yahoo Finance

Indivior s Supernus Merger Could Broaden Its Growth Engine in 2026

INDV's proposed Supernus merger could broaden its CNS portfolio, cut costs and reduce reliance on...

August 7 Business Wire

Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc. - SUPN

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC...

Never miss news about Indivior

Track Indivior and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Indivior competitors & trending companies

Browse news for competitors to Indivior and other trending companies.